Long-acting medications for the hyperkinetic disorders: A note on cost-effectiveness

European Child and Adolescent Psychiatry

Volumn 16, Issue 7, 2007, Pages 421-429

  Schlander, Michael ^a,b,c  

^a Institute for Innovation and Valuation in Health Care (INNOVALHC)   (Germany)

^b Fachhochschule Ludwigshafen   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder (ADHD); Cost effectiveness; Hyperkinetic disorder (HKD); Methylphenidate; Stimulants

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; CENTRAL STIMULANT AGENT;

ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; HOSPITALIZATION; HUMAN; HYPERKINESIA; LONG TERM CARE; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST; COST BENEFIT ANALYSIS; DELAYED RELEASE FORMULATION; ECONOMICS; EUROPE; GERMANY; PRACTICE GUIDELINE; STATISTICAL MODEL; TREATMENT OUTCOME;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DELAYED-ACTION PREPARATIONS; DRUG COSTS; EUROPE; GERMANY; HUMANS; METHYLPHENIDATE; MODELS, ECONOMIC; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TREATMENT OUTCOME;

EID: 38749091784     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-007-0615-2     Document Type: Review

References (94)

1. L Annemans M Ingham 2002 Estimating cost-effectiveness of Concerta OROS in attention-deficit/hyperactivity disorder (ADHD) - adapting the Canadian Coordinating Office for Health Technology Assessment's (CCOHTA) economic model of methylphenidate immediate release versus behavioural interventions from a parent's perspective Value Health 5 6 517
2. JP Bae 2005 Meta-regression assessment of atomoxetine efficacy using randomized controlled ADHD trials Value Health 8 6 A16
3. R Baltussen R Leidl A Ament 1996 Real world designs in economic evaluation: bridging the gap between clinical research and policy-making Pharmacoeconomics 16 5 449 458
4. Banaschewski T, Coghill D, Santosh P, Zuddas A, Ashershon P, Buitelaar J, Danckaerts M, Doepfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen H-C, Sonuga-Barke EJS, Taylor E (2006) Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiat, published online May 5, 2006
5. RA Barkley M Fischer CS Edelbrock L Smallish 1991 The adolescent outcome of hyperactive children diagnosed by research criteria. III. Mother-child interactions, family conflicts and maternal psychopathology J Child Psychol Psychiat 32 233 255
6. M Beneke W Rasmus 1992 "Clinical Global Impressions" (ECDEU): some critical comments Pharmacopsychiatry 25 171 176
7. J Biederman AFT Arnsten SV Faraone AE Doyle TJ Spencer TE Wilens MD Weiss SA Safren L Culpepper 2006 New developments in the treatment of ADHD J Clin Psychiat 67 1 148 159
8. A Briggs A Gray 2000 Using cost effectiveness information Brit Med J 320 246
9. M Buxton MF Drummond BA Van Hout RL Prince TA Sheldon T Szucs M Vray 1997 Modelling in economic evaluation: an unavoidable fact of life Health Econ 6 217 227
10. A Claxton J Cramer C Pierce 2001 A systematic review of the associations between dose regimens and medication compliance Clin Therap 23 8 1296 1310
11. F Dahlke A Lohaus H Gutzmann 1992 Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research Psychopharmacol Bull 28 425 432
12. HA Dakin NJ Devlin IAO Odeyemi 2006 "Yes", "no", or "yes, but?" Multinomial modelling of NICE decision-making Health Policy 77 352 367
13. M Danckaerts E Heptinstall O Chadwick E Taylor 1999 Self-report of attention deficit hyperactivity disorder in adolescents Psychopathology 32 81 92
14. M De Civita D Regier AH Alamgir AH Anis MJ FitzGerald CA Marra 2005 Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications Pharmacoeconomics 23 7 659 685
15. A De Ridder D De Graeve 2002 Estimating willingness to pay for drugs to treat ADHD - a contingent valuation study in students Value Health 5 6 462
16. N Devlin D Parkin 2004 Does NICE have cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis Health Econ 13 437 452
17. P Dolan 2001 Utilitarianism and the measurement and aggregation of quality-adjusted life-years Health Care Anal 9 1 65 76
18. P Dolan R Shaw A Tsuchiya A Williams 2005 QALY maximisation and people's preferences: a methodological review of the literature Health Econ 14 2 197 208
19. M Donnelly MM Haby R Carter G Andrews T Vos 2004 Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder Austr New Zeal J Psychiat 38 592 601
20. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford
21. SV Faraone 2003 Understanding the effect size of ADHD medications: implications for clinical care Medscape 8 1 7
22. M Fischer RA Barkley KE Fletcher L Smallish 1993 The stability of dimensions of behaviour in ADHD and normal children over an 8-year follow-up J Abnormal Child Psychol 21 315 337
23. Foster EM, Jensen PS, Schlander M, Pelham WE, Hechtman L, Arnold LE, Swanson JM, Wigal T (2007) Treatment for ADHD: is more complex treatment cost-effective for more complex cases? Health Services Res 42(1):165-182
24. N Freemantle L Blonde B Bolinder RA Gerber FD Hobbs FD Richard L Martinez S Ross 2005 Real-world trials to answer real-world questions Pharmacoeconomics 23 8 747 754
25. Garber AM (2000) Advances in cost-effectiveness analysis of health interventions. In: Culyer AJ, Newhouse JP (eds) Handbook of health economics, vol 1A. Amsterdam, Elsevier, pp 181-221
26. A Gilmore R Milne 2001 Methylphenidate in children with hyperactivity: review and cost-utility analysis Pharmacoepidemiol Drug Safety 10 85 94
27. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York, NY, Oxford
28. I Griebsch J Coast J Brown 2005 Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health Pediatrics 115 e600 e614
29. Guy W (2000) Clinical Global Impressions (CGI) Scale. In: American Psychiatric Association (APA), Handbook of Psychiatric Measures. Washington, DC, APA, pp 100-102
30. S Hack B Chow 2001 Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance J Child Adolesc Psychopharmacol 11 19 59 67
31. JW Hay 1998 Economic modeling and sensitivity analysis Value Health 1 3 187 193
32. M Iskedjian B Maturi JH Walker TR Einarson S Khattak G Carter 2003 Cost-effectiveness of atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents Value Health 3 6 275
33. PS Jensen JA Garcia S Glied M Crowe M Foster M Schlander S Hinshaw B Vitiello LE Arnold G Elliott L Hechtman JH Newcorn WE Pelham J Swanson K Wells 2005 Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD Am J Psychiat 162 9 1628 1636
34. Jensen PS, Garcia JA, Glied S, Foster EM, Schlander M, and the MTA Cooperative Group (2004) Cost-effectiveness of attention-deficit/hyperactivity disorder (ADHD) treatments: estimates based upon the MTA study. 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP). Book of abstracts. Steinkopff-Verlag, Darmstadt, p 219
35. JE Kemner MJ Lage 2006 Effect of methylphenidate formulation on treatment patterns and use of emergency room services Am J Health Syst Pharm 63 4 317 322
36. JE Kemner MJ Lage 2006 Impact of methylphenidate formulation on treatment patterns and hospitalizations: a retrospective analysis Ann General Psychiat 5 5 1 8
37. Kemner JE, Starr HL, Bowen DL, Ciccone PE, Lynch JM (2004) Greater improvement and response rates with OROS MPH vs atomoxetine in children with ADHD. Presentation at the XXIVth congress of the collegium internationale neuro-psychopharmacologicum, Paris, France, June 20-24, 2004
38. JE Kemner HL Starr PE Ciccone CG Hooper-Wood RS Crocket 2005 Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study Adv Therapy 22 5 498 512
39. King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R (2006) A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 10(23)
40. King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R (2004) A systematic review of the clinical and cost-effectiveness of methylphenidate hydrochloride, dexamfe- tamine sulphate and atomoxetine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. York, December 2004
41. King S, Riemsma R, Hodges Z, Emmans D, Golder S, Drummond M, Weatherly H, Griffin S, Richardson G, Taylor E, Senn S (2004) Technology assessment report for the HTA programme: methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder. Final version. NICE, London, June 2004
42. A Klassen A Miller S Fine 2004 Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder Pediatrics 114 5 541 547
43. M Lage P Hwang 2004 Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment J Child Adolesc Psychopharmacol 14 4 575 581
44. A Laing S Cottrell P Robinson C Veraart D Tilden M Aristides 2005 A modelled economic evaluation comparing atomoxetine with current therapies for the treatment of children with attention-deficit/hyperactivity disorder (ADHD) in The Netherlands Value Health 8 6 A198
45. R Loeber SM Green BB Lahey M Stouthamer-Loeber 1991 Differences and similarities between children, mothers, and teachers as informants on disruptive child behavior J Abnormal Child Psychol 19 75 95
46. JS March SG Silva S Compton M Shapiro R Califf R Krishman 2005 The case for practical clinical trials in psychiatry Am J Psychiat 162 5 836 846
47. A Marchetti R Magar H Lau EL Murphy PS Jensen CK Conners R Findling E Wineburg I Carotenuto TR Einarson M Iskedijan 2001 Pharmacotherapies for attention-defiict/hyperactivity disorder: expected-cost analysis Clin Therap 23 11 1904 1921
48. SC Marcus GJ Wan JE Kemner M Olfson 2005 Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder Arch Pediatr Adolesc Med 159 572 578
49. Miller A, Lee SK, Raina P, Klassen A, Zupancic J, Olsen L (1998) A review of therapies for attention-deficit/hyperactivity disorder. Ottawa, ON, Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
50. AR Miller CE Lalonde KM McGrail 2004 Children's persistence with methylphenidate therapy: a population-based study Can J Psychiat 49 11 761 768
51. MTA Cooperative Group 1999 A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder Arch General Psychiat 56 6 1088 1096
52. MTA Cooperative Group 1999 Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the multimodal treatment study of children with attention-deficit/hyperactivity disorder Arch General Psychiat 56 1088 1096
53. S Narayan J Hay 2004 Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD Expert Rev Pharmacoecon Outcomes Res 4 6 625 634
54. National Institute for Clinical Excellence [NICE] (2004) Guide to the methods of technology appraisal (reference N0515). NICE, London, April 2004
55. National Institute for Clinical Excellence [NICE] (2004) Guideline development methods: information for National Collaborating Centres and guideline developers. NICE, London, February 2004 (updated February 2005)
56. National Institute for Health and Clinical Excellence [NICE] (2006) Technology Appraisal 98: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Review of Technology Appraisal 13. NICE, London, March 2006
57. National Institute for Health and Clinical Excellence [NICE] (2005) Final Appraisal Determination: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. NICE, London, May 2005
58. Newcorn J, Kratochvil CJ, Allen AJ, Milton DR, Moore RJ, Michelson D (2005) Atomoxetine and OROS methylphenidate for the treatment of ADHD: acute results and methodological issues. Poster presentation at 45th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health (NIMH), Boca Raton, FL, June 6-9, 2005, Book of Abstracts, p 188
59. Newcorn JH, Owens JA, Jasinski DR, et al. (2004) Results from recently completed comparator studies with atomoxetine and methylphenidate. 51st Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP), Washington, DC, Symposium 20, October 21, 2004
60. S Ramsey R Willke A Briggs R Brown M Buxton A Chawla J Cook H Glick B Liljas D Petitti S Reed 2005 Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report Value Health 8 5 521 533
61. DA Revicki L Frank 1999 Pharmacoeconomic evaluations in the real world: effectiveness versus efficacy studies Pharmacoeconomics 15 5 423 434
62. Rittenhouse B, O'Brien B (1996) Threats to the validity of pharmacoeconomic analyses based on clinical trial data. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Lippincott-Raven, Philadelphia, PA
63. RJ Sanchez ML Crismon JC Barner T Bettinger JP Wilson 2005 Assessment of adherence measures with different stimulants among children and adolescents Pharmacotherapy 25 7 909 917
64. R Schachar AR Jadad M Gauld M Boyle L Booker A Snider M Kim C Cunningham 2002 Attention-deficit hyperactivity disorder: critical appraisal of extended treatment studies Can J Psychiat 47 4 337 348
65. E Schirm H Tobi JM Zito LTW de Jong-van den Berg 2001 Psychotropic medication in children: a study from the Netherlands Pediatrics 108 2 e25
66. Schlander M (2007) Health technology assessments by the National Institute for Health and Clinical Excellence (NICE): a qualitative study. New York, NY: Springer
67. Schlander M (2007) Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 23 (in press)
68. M Schlander 2007 NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD) Curr Med Res Opin 23 1 207 222
69. Schlander M (2006) Cost-effectiveness of treatment options for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents: what have we learnt? 17th World congress of the international association for child and adolescent psychiatry and allied professions (IACAPAP), Melbourne, September 10-14, 2006. Book of abstracts, p 43 (No. 2040)
70. Schlander M (2005) Kosteneffektivität und Ressourcenallokation: Gibt es einen normativen Anspruch der Gesundheitsoekonomie? In: Kick HA, Taupitz J (eds) Gesundheitswesen zwischen Wirtschaftlichkeit und Menschlichkeit. Muenster, LIT-Verlag, pp 37-112
71. M Schlander 2004 Cost-effectiveness of methylphenidate OROS for attention-deficit/hyperactivity disorder (ADHD): an evaluation from the perspective of the UK National Health Service (NHS) Value Health 7 3 236
72. M Schlander O Schwarz L Hakkaart-van Roijen P Jensen U Persson P Santosh G-E Trott the MTA Cooperative Group 2006 Cost-effectiveness of clinically proven treatment strategies for attention-deficit/ hyperactivity disorder (ADHD) in the United States, Germany, The Netherlands, Sweden, and United Kingdom Value Health 9 6 A312
73. M Schlander O Schwarz L Hakkaart-van Roijen P Jensen U Persson P Santosh G-E Trott the MTA Cooperative Group 2006 Functional impairment of patients with attention-deficit/hyperactivity disorder (ADHD): an alternative cost-effectiveness analysis of clinically proven treatment strategies based upon the NIMH MTA study Value Health 9 6 A312
74. M Schlander O Schwarz EM Foster L Hakkaart-van Roijen P Jensen U Persson P Santosh G-E Trott the MTA Cooperative Group 2006 Cost-effectiveness of clinically proven treatment strategies for attention-deficit/hyperactivity disorder (ADHD): impact of coexisting conditions Value Health 9 6 A309
75. Schlander M, Jensen PS, Foster EM, Schwarz O, the MTA Cooperative Group (2005) Incremental cost-effectiveness ratios of clinically proven treatments for attention-deficit/hyperactivity disorder (ADHD): impact of diagnostic criteria and comorbidity. 5th World Congress, International Health Economics Association (iHEA). Book of abstracts. Barcelona, pp 194-195
76. Schlander M, Trott G-E, Migliaccio-Walle K, Caro JJ (2004) Kosteneffektivitaet alternativer Therapien der Aufmerksamkeits-Defizit- Hyperaktivitaets-Stoerung (ADHS) bei Kindern und Jugendlichen: ein Vergleich von Methylphenidat-OROS einmal taeglich und Methylphenidat dreimal taeglich aus der Perspektive der gesetzlichen Krankenversicherung. Monatsschrift fuer Kinderheilkunde 152:Suppl 1
77. Schlander M, Jensen PS, Foster EM, Garcia JA, Glied S, Croew M, MTA Cooperative Group (2004) Kosteneffektivitaet alternativer Behandlungsstrategien der Aufmerksam-keitsdefizit/Hyperaktivitätsstörung (ADHS): Erste Daten aus der ameri-kanischen MTA-Studie. Monatsschrift für Kinderheilkunde 152:Suppl. 1
78. D Schwartz J Lellouch 1967 Explanatory and pragmatic attitudes in therapeutic trials J Chronic Dis 20 637 648
79. WS Sharp JM Walter WL Marsh GF Ritchie SD Hamburger FX Castellanos 1999 ADHD in girls: clinical comparability of a research sample J Am Acad Child Adolesc Psychiat 38 40 47
80. M Steele M Weiss J Swanson J Wang RS Prinzo CE Binder 2006 A randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release-methylphenidate in Attention-Deficit-Hyperactivity- Disorder Can J Clin Pharmacol 13 1 e50 e62
81. Steele M, Riccardelli R, Binder C (2004) Effectiveness of OROS-methylphenidate vs. usual care with immediate release methylphenidate in ADHD children. Presentation at the American Psychiatric Association (APA) annual meeting, New York, NY, May 1-6th
82. Steinhoff K, Wigal T, Swanson J (2003) Single daily dose ADHD medication effect size evaluation. Poster presentation, 50th annual meeting of the American Academy for Child and Adolescent Psychiatry, Miami, FL, October 22-27, 2003
83. J Swanson 2003 Compliance with stimulants for attention-deficit/ hyperactivity disorder. Issues and approaches for improvement CNS Drugs 17 2 117 131
84. J Swanson S Gupta A Lam I Shoulson M Lerner N Modi E Lindemulder S Wigal 2003 Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies Arch General Psychiat 60 2 204 211
85. JM Swanson HC Kraemer SP Hinshaw LE Arnold CK Conners HB Abikoff W Clevenger M Davies GR Elliott LL Greenhill L Hechtman B Hoza PS Jensen JS March JH Newcorn EB Owens WE Pelham E Schiller JB Severe S Simpson B Vitiello K Wells T Wigal M Wu 2001 Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment J Am Acad Child Adolesc Psychiat 40 2 168 179
86. E Taylor M Doepfner J Sergeant P Asherson T Banaschewski J Buitelaar D Coghill M Danckaerts A Rothenberger E Sonuga-Barke H-C Steinhausen A Zuddas 2004 European guidelines for hyperkinetic disorder - first upgrade Eur Child Adolesc Psychiat 13 Suppl 1 7 30
87. D Tilden R Richardson K Nyhus P Robinson S Cottrell 2005 A modelled economic evaluation of atomoxetine (Strattera) for the treatment of three patient subgroups with attention deficit hyperactivity disorder Value Health 8 6 A197
88. Towse A, Pritchard C, Devlin N (2002) Cost-effectiveness thresholds: economic and ethical issues. King's Fund and Office of Health Economics, London
89. MC Weinstein B O'Brien J Hornberger J Jackson M Johannesson C McCabe BR Luce 2003 Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices - modeling studies Value Health 6 1 9 17
90. MC Weinstein EL Toy EA Sandberg PJ Neumann JS Evans KM Kuntz JD Graham JK Hammitt 2001 Modeling for health care and other policy decisions: uses, roles, and validity Value Health 4 5 348 361
91. M Weiss K Gadow MB Wasdell 2006 Effectiveness outcomes in attention-deficit/hyperactivity disorder J Clin Psychiat 67 Suppl 8 38 45
92. Williams A (2004) What could be nicer than NICE? Annual Lecture 2004. Office of Health Economics, London
93. World Health Organization (2003) Technology appraisal programme of the National Institute for Clinical Excellence. A review by WHO. June-July 2003. Copenhagen: World Health Organization (WHO). Available online at http://www.nice.org.uk/Docref.asp?d=85797. Last accessed June 30, 2004
94. Zupancic JAF, Miller A, Raina P, Lee SK, Klassen A, Olsen L (1998) Economic evaluation of pharmaceutical and psychological/behavioural therapies for attention-deficit/hyperactivity disorder. In: Miller A, Lee SK, Raina P, Klassen A, Zupancic J, Olsen L (eds) A review of therapies for attention-deficit/hyperactivity disorder. Canadian Coordinating Office for Health Technology Assessment (CCOHTA), Ottawa, ON